Celgene (NASDAQ:CELG) has been given a $127.00 target price by analysts at SunTrust Banks in a research note issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price target indicates a potential upside of 21.69% from the company’s previous close.
A number of other equities analysts have also recently issued reports on the company. Morgan Stanley cut Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 target price on shares of Celgene in a report on Monday, October 30th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 target price on Celgene and gave the stock a “buy” rating in a report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $132.63.
Celgene (CELG) traded down $0.39 during midday trading on Monday, hitting $104.36. The stock had a trading volume of 4,495,827 shares, compared to its average volume of 4,824,942. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market capitalization of $82,243.13, a P/E ratio of 24.79, a P/E/G ratio of 0.81 and a beta of 1.78.
Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. increased its holdings in Celgene by 0.9% in the 1st quarter. Prudential Financial Inc. now owns 2,763,704 shares of the biopharmaceutical company’s stock valued at $343,887,000 after purchasing an additional 24,250 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Celgene by 10.0% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 58,050 shares of the biopharmaceutical company’s stock worth $7,223,000 after purchasing an additional 5,272 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Celgene by 2.8% during the first quarter. Stifel Financial Corp now owns 1,215,960 shares of the biopharmaceutical company’s stock worth $151,182,000 after purchasing an additional 32,748 shares during the last quarter. Glenview Trust Co lifted its position in shares of Celgene by 5.4% during the first quarter. Glenview Trust Co now owns 70,484 shares of the biopharmaceutical company’s stock worth $8,771,000 after purchasing an additional 3,628 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Celgene by 205.4% during the first quarter. SG Americas Securities LLC now owns 140,738 shares of the biopharmaceutical company’s stock worth $17,512,000 after purchasing an additional 274,314 shares during the last quarter. Institutional investors own 79.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by American Market News and is the property of of American Market News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/29/celgene-celg-given-a-127-00-price-target-at-suntrust-banks.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
